Involvement of A3 receptors in the potentiation by adenosine of the inhibitory effect of theophylline on human eosinophil degranulation: Possible novel mechanism of the anti-inflammatory action of theophylline

Biochemical Pharmacology

Volumn 61, Issue 12, 2001, Pages 1551-1559

  Ezeamuzie, Charles I ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

A3 receptors; Adenosine; Asthma; Degranulation; Eosinophil; Theophylline

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 9 CHLORO 2 (2 FURYL) 5 PHENYLACETYLAMINO 1,2,4 TRIAZOLO[1,5 C]QUINAZOLINE; ADENOSINE; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR STIMULATING AGENT; COMPLEMENT COMPONENT C5A; N6 (3 IODOBENZYL) 5N METHYLCARBAMOYLADENOSINE; PEROXIDASE; PHOSPHODIESTERASE IV; ROLIPRAM; THEOPHYLLINE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEGRANULATION; ENZYME INHIBITION; ENZYME RELEASE; EOSINOPHIL; HUMAN; HUMAN CELL; INHIBITION KINETICS; PRIORITY JOURNAL;

ADENOSINE; ANTI-INFLAMMATORY AGENTS; CELL DEGRANULATION; DRUG INTERACTIONS; DRUG SYNERGISM; EOSINOPHIL PEROXIDASE; EOSINOPHILS; HUMANS; PEROXIDASES; RECEPTOR, ADENOSINE A3; RECEPTORS, PURINERGIC P1; THEOPHYLLINE;

EID: 0035877185     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(01)00613-X     Document Type: Article

References (44)

1. Pauwels R.A. New aspects of the therapeutic potential of theophylline in asthma. J Allergy Clin Immunol. 83:1989;548-553.
2. Barnes P.J., Pauwels R.A. Theophylline in the management of asthma time for reappraisal? Eur Respir J. 7:1994;579-591.
3. Page C.P. Recent advances in our standing of theuse of theophylline in the treatment of asthma. J Clin Pharmacol. 39:1999;237-240.
4. Sullivan P.J., Bekir S., Jaffer Z., Page C., Jeffery P., Costello J. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet. 343:1994;1006-1008.
5. Banner K.H., Page C.P. Anti-inflammatory effects of theophylline and selective phosphodiesterase inhibitors. Clin Exp Allergy. 26:(Suppl 2):1996;2-9.
6. Frigas E., Gleich G.J. The eosinophil and the pathophysiology of asthma. J Allergy Clin Immunol. 77:1986;527-537.
7. Barnes P.J. New concepts in pathogenesis of bronchial hyperresponsiveness and asthma. J Allergy Clin Immunol. 83:1989;1013-1026.
8. Motijima S., Frigas E., Leogering D.A., Gleich G.J. Toxicity of eosinophil proteins for guinea pig tracheal epithelium in vitro. Am Rev Respir Dis. 139:1989;801-805.
9. Laitinen L.A., Heins M., Laitinen A., Kava T., Haahtela T. Damage of the airway epithelium and bronchial reactivity in patients with asthma. Am Rev Respir Dis. 131:1985;599-606.
10. Kita H., Abu-Ghazaleh R.I., Gleich G.J., Abraham R.T. Regulation of Ig-induced eosinophil degranulation by adenosine 3,5, cyclic monophosphate. J Immunol. 146:1991;2712-2718.
11. Hatzelmann A., Tenor H., Schudt C. Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions. Br J Pharmacol. 114:1995;821-831.
12. Tenor H., Hatzelmann A., Church M.K., Schudt C., Shute J.K. Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Br J Pharmacol. 118:1996;1727-1735.
13. Bergstrand H. Phosphodiesterase inhibition and theophylline. Eur J Respir Dis. 61:1980;37-44.
14. Fredholm B.B., Persson C.G.A. Xanthine derivatives as adenosine antagonists. Eur J Pharmacol. 81:1982;673-676.
15. Dent G., Giembycz M.A., Rabe K.F., Barnes P.J. Inhibition of eosinophil cyclic nucleotide PDE activity and opsonized zymosan-stimulated respiratory burst by type IV-selective PDE inhibitors. Br J Pharmacol. 103:1991;1339-1346.
16. Barnes P.J. Cyclic nucleotides and phosphodiesterases and airways functions. Eur Respir J. 8:1995;457-462.
17. Schudt C., Tenor H., Hatzelmann A. PDE isoenzymes as targets for antiasthma drugs. Eur Respir J. 8:1995;1179-1183.
18. Cohan V.L., Showell H.J., Fisher D.A., Pazoles C.J., Watson J.W., Turner C.R., Cheng J.B. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633. J Pharmacol Exp Ther. 278:1996;1356-1361.
19. Rang H.P., Dale M.M. Pharmacology. 1991;Churchill Livingstone, Edinburgh.
20. 3 adenosine receptor. Biochem Biophys Acta. 1179:1993;105-107.
21. 3 adenosine receptor. Proc Natl Acad Sci USA. 90:1993;10365-10369.
22. 3 receptor expression and function in eosinophils. Am J Respir Cell Mol Biol. 16:1997;531-537.
23. 3 receptors on human eosinophils mediate inhibition of degranulation and superoxide anion release. Br J Pharmacol. 127:1999;188-194.
24. 3 receptor stimulation inhibits migration of human eosinophils. J Leukoc Biol. 62:1997;465-468.
25. Hansel T.T., De Vries I.J.M., Iff T., Ris S., Wandzilak M., Betz S., Blaser K., Walker C. An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. J Immunol Meth. 145:1991;105-110.
26. Kroegel C., Yukawa T., Dent G., Venge P., Chung K.F., Barnes P.J. Stimulation of degranulation from eosinophils by platelet activating factor. J Immunol. 142:1989;3518-3526.
27. 3 adenosine receptor-selective antagonists. Neuropharmacology. 36:1997;1157-1165.
28. Shute J.K., Tenor H., Church M.K., Holgate S.T. Theophylline inhibits the release of eosinophil survival cytokines - is Raf-1 the protein kinase A target. Clin Expt Allergy. 28:(Suppl.3):1998;47-52.
29. i. Mol Pharmacol. 34:1988;37-41.
30. Tomes C., Rossi S., Moreno S. Isobutylmethylxanthine and other classical cyclic nucleotide phosphodiesterase inhibitors affect cAMP-dependent protein kinase activity. Cell Signal. 5:1993;615-621.
31. 3 receptor subtype. J Med Chem. 39:1996;4142-4148.
32. 3 adenosine receptor . Proc Natl Acad Sci USA. 89:1992;7432-7436.
33. Yukawa T., Kroegel C., Chanez P., Dent G., Ukena D., Chung K.F., Barnes P.J. Effect of theophylline and adenosine on eosinophil function. Am Rev Respir Dis. 140:1989;327-333.
34. Ezeamuzie C.I., Al-Hage M., Nwankwoala R.N.P. The effect of salmeterol on human eosinophils is both stimulus- and response-dependent. Int J Immunopharmacol. 19:1997;421-430.
35. Driver A.G., Kukoly C.A., Ali S., Mustafa S.J. Adenosine in bronchoalveolar lavage fluid in asthma. Am Rev Respir Dis. 148:1993;91-97.
36. Cushley M.J., Tattersfield A.E., Holgate S.T. Inhaled adenosine and guanosine on airway resistance in normal and asthmatic subjects. Br J Clin Pharmacol. 15:1983;161-165.
37. Church M., Holgate S. Adenosine-induced bronchoconstriction and its inhibition by nedocromil sodium. J Allergy Clin Immunol. 93:1993;190-194.
38. El-Hashim A., D'Agostino B., Matera M.G., Page C.P. Characterization of adenosine receptors involved in adenosine-induced bronchoconstriction in an allergic rabbit model. Br J Pharmacol. 119:1996;1262-1268.
39. 1 receptors inhibiting allergen-induced airway responsiveness in allergec rabbits. Nature. 97:1997;721-725.
40. Mann J.S., Holgate S.T. Specific antagonism of adenosine-induced bronchoconstriction in asthma by oral theophylline. Br J Clin Pharmacol. 19:1985;685-692.
41. Pauwels R., Van Rebterghem D., Van Der Straeten M., Johanesson N., Persson C.G.A. The effect of theophylline and enprofylline on allergen-induced bronchoconstriction. J Allergy Clin Immunol. 76:1985;583-589.
42. 3 receptors by in-situ hybridization in human lung. FASEB J. 8:1994;A800.
43. Yasui K., Hu B., Nakazawa T., Agematsu K., Komiyama A. Theophylline accelerates human granulocyte apoptosis not via phosphodiesterase inhibition. J Clin Invest. 7:1997;1677-1684.
44. i and induces apoptosis. Drug Dev Res. 37:1996;182.